ZA954641B - Polynucleotide vaccine for papilloma virus - Google Patents

Polynucleotide vaccine for papilloma virus

Info

Publication number
ZA954641B
ZA954641B ZA954641A ZA954641A ZA954641B ZA 954641 B ZA954641 B ZA 954641B ZA 954641 A ZA954641 A ZA 954641A ZA 954641 A ZA954641 A ZA 954641A ZA 954641 B ZA954641 B ZA 954641B
Authority
ZA
South Africa
Prior art keywords
pct
papilloma virus
sec
polynucleotide vaccine
date
Prior art date
Application number
ZA954641A
Other languages
English (en)
Inventor
John J Donnelly
Margaret A Liu
Douglas Martinez
Donna L Montgomery
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of ZA954641B publication Critical patent/ZA954641B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA954641A 1994-06-30 1995-06-06 Polynucleotide vaccine for papilloma virus ZA954641B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26842494A 1994-06-30 1994-06-30

Publications (1)

Publication Number Publication Date
ZA954641B true ZA954641B (en) 1996-01-26

Family

ID=23022939

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA954641A ZA954641B (en) 1994-06-30 1995-06-06 Polynucleotide vaccine for papilloma virus

Country Status (20)

Country Link
US (1) US5866553A (hu)
EP (1) EP0768893B1 (hu)
JP (1) JPH10501987A (hu)
CN (1) CN1156966A (hu)
AT (1) ATE233101T1 (hu)
AU (1) AU701973B2 (hu)
CA (1) CA2193365C (hu)
CZ (1) CZ375296A3 (hu)
DE (1) DE69529748T2 (hu)
ES (1) ES2191052T3 (hu)
FI (1) FI965224A (hu)
HU (1) HU220747B1 (hu)
IL (1) IL113817A (hu)
MX (1) MX9700229A (hu)
NO (1) NO965590L (hu)
NZ (1) NZ288045A (hu)
PL (1) PL180639B1 (hu)
SK (1) SK164196A3 (hu)
WO (1) WO1996000583A1 (hu)
ZA (1) ZA954641B (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6995008B1 (en) * 1994-03-07 2006-02-07 Merck & Co., Inc. Coordinate in vivo gene expression
US5736524A (en) * 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
FR2751879B1 (fr) * 1996-07-30 1998-10-30 Transgene Sa Composition pharmaceutique contre les tumeurs et infections a papillomavirus
US7118754B1 (en) 1996-07-30 2006-10-10 Transgene S.A. Pharmaceutical composition for treating papillomavirus tumors and infection
DE19631357A1 (de) * 1996-08-02 1998-02-05 Deutsches Krebsforsch Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
EP1017283B1 (en) * 1997-02-14 2004-12-15 Merck & Co., Inc. Polynucleotide vaccine formulations
US6183746B1 (en) 1997-10-09 2001-02-06 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
CA2229955C (en) 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
US7182947B2 (en) 1998-02-20 2007-02-27 Medigene Ag Papillomavirus truncated L1 protein and fusion protein constructs
US20020039584A1 (en) 1998-02-20 2002-04-04 Medigene Ag Papilloma virus capsomere vaccine formulations and methods of use
US7494658B2 (en) 1998-02-20 2009-02-24 Medigene Ag Papilloma virus truncated L1 protein and fusion protein constructs
US6926897B1 (en) 1998-03-24 2005-08-09 Medigene Aktiengesellschaft Medicament for the avoidance or treatment of papillomavirus-specific tumour
EP1071377A1 (en) * 1998-04-14 2001-01-31 Merck & Co., Inc. Needleless administration of polynucleotide formulations
AU766403C (en) * 1998-09-04 2004-05-27 Aventis Pasteur Limited Treatment of cervical cancer
US20040258763A1 (en) * 1999-02-03 2004-12-23 Bell Steve J.D. Methods of manufacture and use of calcium phosphate particles containing allergens
US20020054914A1 (en) * 1999-02-03 2002-05-09 Tulin Morcol Compositions and methods for therapuetic agents complexed with calcium phosphate and encased by casein
MXPA01007895A (es) 1999-02-03 2003-07-21 Biosante Pharmaceuticals Inc Particulas terapeuticas de fosfato de calcio, metodos de manufactura y usos.
ES2308069T3 (es) * 1999-03-26 2008-12-01 Vical Incorporated Composiciones adyuvantes para realzar inmunorespuestas a las vacunas polinucleotido-basadas.
EP2368575B1 (en) * 1999-04-08 2014-10-01 Intercell USA, Inc. Dry formulation for transcutaneous immunization
US7001995B1 (en) 1999-08-25 2006-02-21 Merck & Co., Inc. Synthetic human papillomavirus genes
CA2381991A1 (en) * 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic human papillomavirus genes
KR100366608B1 (ko) * 2000-02-15 2003-01-09 마스터진(주) 형질전환 식물체로부터 생산된 재조합 인간 파필로마바이러스 백신
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
SE0002498D0 (sv) * 2000-07-03 2000-07-03 Stefan Schwartz Papillomavirus vaccine
KR20020005332A (ko) * 2000-07-10 2002-01-17 정상훈 탈모증 치료용 키트
WO2002064162A2 (en) * 2001-02-13 2002-08-22 Government Of The United States, As Represented By The Secretary Of The Army Vaccine for transcutaneous immunization
WO2003000283A1 (en) * 2001-06-22 2003-01-03 The Wistar Institute Of Anatomy And Biology Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein
DE10137102A1 (de) * 2001-07-30 2003-02-27 Deutsches Krebsforsch Polyvalente Vakzine gegen durch Papillomaviren verursachte Erkrankungen, Verfahren zu deren Herstellung und deren Verwendung
US20030185892A1 (en) * 2001-08-17 2003-10-02 Bell Steve J. D. Intraocular delivery compositions and methods
US20030228327A1 (en) * 2001-11-05 2003-12-11 Lasher Alfred W. DNA-based plasmid formulations and vaccines and prophylactics containing the same
DK1585812T3 (en) 2002-12-13 2017-04-10 Alphavax Inc MULTI-ANTI-ANTI-ANTI-VIRUS REPLICATE PARTICLES AND PROCEDURES
CN1993113B (zh) * 2004-02-13 2010-12-08 Nod药物公司 包含磷酸钙纳米颗粒核心，生物分子和胆汁酸的颗粒，其生产方法，其治疗用途
EP1811941A4 (en) * 2004-11-01 2008-09-10 Biosante Pharmaceuticals Inc CALCIUM PHOSPHATE THERAPEUTIC PARTICLES FOR AESTHETIC OR COSMETIC MEDICINE, AND METHODS OF MAKING AND USING THE SAME
CA2596698C (en) * 2005-02-01 2017-05-16 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Papillomavirus l2 n-terminal peptides for the induction of broadly cross-neutralizing antibodies
US9428555B2 (en) * 2007-04-29 2016-08-30 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of Human Papillomavirus type 16
US9364529B2 (en) 2007-04-29 2016-06-14 Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. Truncated L1 protein of human papillomavirus type 18
CN101343315B (zh) * 2007-05-29 2012-06-13 厦门大学 截短的人乳头瘤病毒6型l1蛋白
CN105209063A (zh) * 2013-03-15 2015-12-30 宾夕法尼亚大学理事会 具有抗原和作为佐剂的白细胞介素-23的疫苗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497796A (en) * 1980-03-26 1985-02-05 The Regents Of The University Of California Gene transfer in intact mammals
EP0217919B1 (en) * 1985-04-04 1992-08-05 Georgetown University Type-specific papillomavirus dna sequences and peptides
US4777239A (en) * 1986-07-10 1988-10-11 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic peptides of human papilloma virus
EP1026253B2 (en) * 1989-03-21 2012-12-19 Vical Incorporated Expression of exogenous polynucleotide sequences in a vertebrate
DE122007000016I1 (de) * 1991-07-19 2007-05-24 Univ Queensland Impfstoffe gegen Papillomavirus
US5376542A (en) * 1992-04-27 1994-12-27 Georgetown University Method for producing immortalized cell lines using human papilluma virus genes
PT586076E (pt) * 1992-08-07 2003-11-28 Wyeth Corp Vacinas de adenovirus recombinantes
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
US5593972A (en) * 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization

Also Published As

Publication number Publication date
AU701973B2 (en) 1999-02-11
CZ375296A3 (en) 1997-08-13
PL180639B1 (pl) 2001-03-30
MX9700229A (es) 1997-04-30
DE69529748T2 (de) 2003-10-16
CN1156966A (zh) 1997-08-13
FI965224A0 (fi) 1996-12-27
NO965590D0 (no) 1996-12-27
DE69529748D1 (de) 2003-04-03
CA2193365A1 (en) 1996-01-11
US5866553A (en) 1999-02-02
PL317874A1 (en) 1997-04-28
FI965224A (fi) 1996-12-27
IL113817A0 (en) 1995-08-31
HUT76446A (en) 1997-09-29
JPH10501987A (ja) 1998-02-24
CA2193365C (en) 2007-04-03
EP0768893A1 (en) 1997-04-23
HU9603562D0 (en) 1997-02-28
IL113817A (en) 2001-03-19
SK164196A3 (en) 1997-08-06
AU2694595A (en) 1996-01-25
NO965590L (no) 1997-02-28
HU220747B1 (hu) 2002-05-28
ES2191052T3 (es) 2003-09-01
NZ288045A (en) 1998-08-26
WO1996000583A1 (en) 1996-01-11
ATE233101T1 (de) 2003-03-15
EP0768893B1 (en) 2003-02-26

Similar Documents

Publication Publication Date Title
ZA954641B (en) Polynucleotide vaccine for papilloma virus
HK1034039A1 (en) Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
FI960977A (fi) Bakteeriperäiset eksportoidut proteiinit ja niihin perustuvat asellulaariset rokotteet
WO1996010419A3 (en) Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule
HK1002017A1 (en) Lyospheres comprising gonadotropin
TR200001835T2 (tr) Aşı.
HK1012017A1 (en) Lipopeptid-derivatives, process for their preparation and their use
IL134392A0 (en) Vaccine against hpv
PL307049A1 (en) Vaccines against pseudohydrophobia and other animal diseases caused by pseudohydrophobia viruses
IL113782A (en) Compositions containing flubendazole their preparation and their use
ES8704911A1 (es) Procedimiento para la obtencion de 1,3,5-triazintrionas
ZA937652B (en) New bacterium causing poultry disease and vaccine derived thereof
DE69332652D1 (de) Verbesserungen in bezug auf die herstellung von malariaimpstoffen
TR200400907T4 (tr) Beta D 5-Tiyoksiloz türevleri, bunları hazırlama yöntemi ve bunların terapötik kullanımları
IT9022476A0 (it) Ceppo asporigeno di bacillus subtilis e suo impiego come ospite per la preparazione di prodotti eterologfhi
SE9401596D0 (sv) New compounds
EP0861077A4 (en) HEMOREGULATORY COMPOUNDS